Passage Bio, Inc. (PASG)

Market Cap	36.35M
Revenue (ttm)	n/a
Net Income (ttm)	-76.57M
Shares Out	61.77M
EPS (ttm)	-1.35
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	235,653
Open	0.571
Previous Close	0.580
Day's Range	0.560 - 0.606
52-Week Range	0.540 - 1.790
Beta	1.19
Analysts	Strong Buy
Price Target	9.00 (+1,429.31%)
Earnings Date	Nov 11, 2024

About PASG

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding β-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment o...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 28, 2020
• Employees: 58
• Stock Exchange: NASDAQ
• Ticker Symbol: PASG
• Website: https://www.passagebio.com

Analyst Forecast

According to 2 analysts, the average rating for PASG stock is "Strong Buy." The 12-month stock price forecast is $9.0, which is an increase of 1,429.31% from the latest price.

Price Target

$9.0

(1,429.31% upside)

Analyst Consensus: Strong Buy